$6.27
+0.02
(+0.4%)▲
Insights on Mimedx Group, Inc.
Revenue is up for the last 4 quarters, 71.67M → 86.83M (in $), with an average increase of 6.1% per quarter
Netprofit is up for the last 4 quarters, -4.98M → 62.68M (in $), with an average increase of 228.9% per quarter
In the last 3 years, Novo Nordisk A/s has given 239.5% return, outperforming this stock by 280.8%
1.44%
Downside
Day's Volatility :2.06%
Upside
0.63%
43.7%
Downside
52 Weeks Volatility :61.92%
Upside
32.36%
Period | Mimedx Group, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -22.33% | 0.5% | 0.0% |
6 Months | 1.88% | 11.7% | 0.0% |
1 Year | 75.92% | 6.2% | 2.2% |
3 Years | -41.25% | 13.5% | -23.0% |
Market Capitalization | 949.0M |
Book Value | $0.98 |
Earnings Per Share (EPS) | 0.43 |
PE Ratio | 14.95 |
PEG Ratio | 2.97 |
Wall Street Target Price | 12.5 |
Profit Margin | 18.11% |
Operating Margin TTM | 17.84% |
Return On Assets TTM | 11.3% |
Return On Equity TTM | 62.09% |
Revenue TTM | 321.5M |
Revenue Per Share TTM | 2.76 |
Quarterly Revenue Growth YOY | 16.7% |
Gross Profit TTM | 219.5M |
EBITDA | 40.5M |
Diluted Eps TTM | 0.43 |
Quarterly Earnings Growth YOY | 4.0 |
EPS Estimate Current Year | 0.31 |
EPS Estimate Next Year | 0.39 |
EPS Estimate Current Quarter | 0.07 |
EPS Estimate Next Quarter | 0.04 |
What analysts predicted
Upside of 99.36%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 359.1M | ↑ 11.82% |
Net Income | -30.0M | ↓ 146.32% |
Net Profit Margin | -8.35% | ↓ 28.51% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 359.1M | ↑ 0.0% |
Net Income | -30.0M | ↑ 0.0% |
Net Profit Margin | -8.35% | ↑ 0.0% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 248.2M | ↓ 30.88% |
Net Income | -49.3M | ↑ 64.4% |
Net Profit Margin | -19.85% | ↓ 11.5% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 258.6M | ↑ 4.18% |
Net Income | -10.3M | ↓ 79.13% |
Net Profit Margin | -3.98% | ↑ 15.87% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 267.8M | ↑ 3.57% |
Net Income | -30.2M | ↑ 193.6% |
Net Profit Margin | -11.27% | ↓ 7.29% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 321.5M | ↑ 20.03% |
Net Income | 67.4M | ↓ 323.33% |
Net Profit Margin | 20.98% | ↑ 32.25% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 67.7M | ↑ 1.21% |
Net Income | -8.4M | ↓ 22.47% |
Net Profit Margin | -12.45% | ↑ 3.8% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 74.4M | ↑ 9.88% |
Net Income | -415.0K | ↓ 95.07% |
Net Profit Margin | -0.56% | ↑ 11.89% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 71.7M | ↓ 3.63% |
Net Income | -5.0M | ↑ 1100.72% |
Net Profit Margin | -6.95% | ↓ 6.39% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 81.3M | ↑ 13.37% |
Net Income | 1.2M | ↓ 124.08% |
Net Profit Margin | 1.48% | ↑ 8.43% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 81.7M | ↑ 0.56% |
Net Income | 6.8M | ↑ 463.42% |
Net Profit Margin | 8.27% | ↑ 6.79% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 86.8M | ↑ 6.27% |
Net Income | 62.7M | ↑ 827.2% |
Net Profit Margin | 72.19% | ↑ 63.92% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 122.8M | ↑ 1.31% |
Total Liabilities | 73.2M | ↑ 54.22% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 122.8M | ↑ 0.0% |
Total Liabilities | 73.2M | ↑ 0.0% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 202.0M | ↑ 64.46% |
Total Liabilities | 202.2M | ↑ 176.25% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 187.9M | ↓ 6.98% |
Total Liabilities | 187.8M | ↓ 7.09% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 171.4M | ↓ 8.78% |
Total Liabilities | 189.4M | ↑ 0.84% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 239.0M | ↑ 39.44% |
Total Liabilities | 96.3M | ↓ 49.14% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 172.8M | ↑ 2.45% |
Total Liabilities | 192.3M | ↑ 114.22% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 171.4M | ↓ 0.79% |
Total Liabilities | 189.4M | ↓ 1.51% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 168.2M | ↓ 1.91% |
Total Liabilities | 186.1M | ↓ 1.75% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 176.4M | ↑ 4.89% |
Total Liabilities | 189.0M | ↑ 1.58% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 189.0M | ↑ 7.17% |
Total Liabilities | 187.7M | ↓ 0.72% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 239.0M | ↑ 26.47% |
Total Liabilities | 96.3M | ↓ 48.68% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 35.8M | ↓ 43.13% |
Investing Cash Flow | -9.2M | ↑ 70.84% |
Financing Cash Flow | -8.9M | ↓ 85.21% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 35.8M | ↑ 0.0% |
Investing Cash Flow | 504.0K | ↓ 105.47% |
Financing Cash Flow | -8.9M | ↑ 0.0% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -39.4M | ↓ 210.1% |
Investing Cash Flow | -4.6M | ↓ 1003.77% |
Financing Cash Flow | 62.9M | ↓ 803.59% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -2.0M | ↓ 94.97% |
Investing Cash Flow | -3.4M | ↓ 25.47% |
Financing Cash Flow | -3.4M | ↓ 105.33% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -17.9M | ↑ 802.77% |
Investing Cash Flow | -2.7M | ↓ 21.65% |
Financing Cash Flow | -580.0K | ↓ 82.7% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 959.0K | ↓ 131.91% |
Investing Cash Flow | -374.0K | ↓ 12.82% |
Financing Cash Flow | 130.0K | ↓ 50.0% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.6M | ↓ 686.44% |
Investing Cash Flow | -1.7M | ↑ 356.95% |
Financing Cash Flow | 66.0K | ↓ 49.23% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.0M | ↓ 28.02% |
Investing Cash Flow | -677.0K | ↓ 60.39% |
Financing Cash Flow | -4.0K | ↓ 106.06% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 7.8M | ↓ 292.07% |
Investing Cash Flow | -348.0K | ↓ 48.6% |
Financing Cash Flow | 4.0K | ↓ 200.0% |
Sell
Neutral
Buy
Mimedx Group, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Mimedx Group, Inc. | -18.04% | 1.88% | 75.92% | -41.25% | -13.62% |
Moderna, Inc. | -1.15% | 39.75% | -18.77% | -40.22% | 304.34% |
Regeneron Pharmaceuticals, Inc. | -7.56% | 12.46% | 14.48% | 77.72% | 159.17% |
Novo Nordisk A/s | -2.8% | 32.13% | 52.48% | 239.51% | 414.16% |
Vertex Pharmaceuticals Incorporated | -4.96% | 10.08% | 23.01% | 83.3% | 130.08% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Mimedx Group, Inc. | 14.95 | 14.95 | 2.97 | 0.31 | 0.62 | 0.11 | NA | 0.98 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Mimedx Group, Inc. | Buy | $949.0M | -13.62% | 14.95 | 18.11% |
Moderna, Inc. | Buy | $41.7B | 304.34% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 159.17% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 414.16% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 130.08% | 28.81 | 36.68% |
Essex Woodlands Health Ventures
BlackRock Inc
Vanguard Group Inc
State Street Corporation
Paradigm Capital Management, Inc.
Geode Capital Management, LLC
mimedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. the company processes the human placental tissue utilizing its proprietary purion® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. mimedx has supplied more than two million allografts, through both direct and consignment shipments. for additional information, please visit www.mimedx.com.
Organization | Mimedx Group, Inc. |
Employees | 895 |
CEO | Mr. William F. Hulse IV |
Industry | Biotechnology |